# The role of ANLN in malignant tumors: pathogenesis, treatment resistance and targeted strategies

## TL;DR

ANLN is a protein involved in cell division that is overexpressed in several cancers, contributing to tumor growth and treatment resistance, making it a potential target for new therapies.

## Contribution

This review systematically explores ANLN's role in cancer progression and treatment resistance, offering new biological insights for precision oncology.

## Key findings

- ANLN is overexpressed in lung, breast, and liver cancers and promotes tumor cell proliferation and invasion.
- ANLN contributes to resistance against chemotherapy, targeted therapy, and immunotherapy through multiple mechanisms.
- ANLN is a promising biomarker and therapeutic target for overcoming treatment resistance in cancer.

## Abstract

ANLN is a highly conserved actin-binding protein that plays a critical role in cytokinesis by interacting with key cytoskeletal components such as actin, myosin, and RhoA. Increasing evidence shows that ANLN is aberrantly overexpressed in various cancers, including lung, breast, and liver cancers, and that its elevated expression is associated with enhanced tumor cell proliferation, migration, and invasion. Because of its central involvement in tumorigenesis and disease progression, ANLN has emerged as a promising prognostic biomarker and potential therapeutic target. Recent studies have demonstrated that ANLN contributes to resistance to chemotherapy, targeted therapy, and immunotherapy through multiple molecular mechanisms. This review provides a systematic overview of the physiological functions of ANLN, its roles in cancer initiation and progression, and its regulatory mechanisms in treatment resistance, offering biological insights into precision oncology and potential strategies for overcoming therapeutic resistance in cancer.